185 related articles for article (PubMed ID: 18664466)
1. High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction.
Sjögren P; Fredrikson GN; Samnegard A; Ericsson CG; Ohrvik J; Fisher RM; Nilsson J; Hamsten A
Eur Heart J; 2008 Sep; 29(18):2218-26. PubMed ID: 18664466
[TBL] [Abstract][Full Text] [Related]
2. Circulating autoantibodies against the apolipoprotein B-100 peptides p45 and p210 in relation to the occurrence of carotid plaques in 64-year-old women.
Fagerberg B; Prahl Gullberg U; Alm R; Nilsson J; Fredrikson GN
PLoS One; 2015; 10(3):e0120744. PubMed ID: 25768285
[TBL] [Abstract][Full Text] [Related]
3. Low levels of IgG autoantibodies against the apolipoprotein B antigen p210 increases the risk of cardiovascular death after carotid endarterectomy.
Asciutto G; Dias NV; Edsfeldt A; Alm R; Fredrikson GN; Gonçalves I; Nilsson J
Atherosclerosis; 2015 Apr; 239(2):289-94. PubMed ID: 25682025
[TBL] [Abstract][Full Text] [Related]
4. Autoantibodies to oxidized low density lipoprotein in relation with coronary artery disease.
Soto Y; Conde H; Aroche R; Brito V; Luaces P; Nasiff A; Obregón A; Vázquez López AM
Hum Antibodies; 2009; 18(3):109-17. PubMed ID: 19729805
[TBL] [Abstract][Full Text] [Related]
5. Autoantibody against the amino acid sequence 661-680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events.
Fredrikson GN; Schiopu A; Berglund G; Alm R; Shah PK; Nilsson J
Atherosclerosis; 2007 Oct; 194(2):e188-92. PubMed ID: 17214995
[TBL] [Abstract][Full Text] [Related]
6. High levels of IgM against methylglyoxal-modified apolipoprotein B100 are associated with less coronary artery calcification in patients with type 2 diabetes.
Engelbertsen D; Anand DV; Fredrikson GN; Hopkins D; Corder R; Shah PK; Lahiri A; Nilsson J; Bengtsson E
J Intern Med; 2012 Jan; 271(1):82-9. PubMed ID: 21668821
[TBL] [Abstract][Full Text] [Related]
7. Plasma autoantibodies against apolipoprotein B-100 peptide 210 in subclinical atherosclerosis.
McLeod O; Silveira A; Fredrikson GN; Gertow K; Baldassarre D; Veglia F; Sennblad B; Strawbridge RJ; Larsson M; Leander K; Gigante B; Kauhanen J; Rauramaa R; Smit AJ; Mannarino E; Giral P; Humphries SE; Tremoli E; de Faire U; Ohrvik J; Nilsson J; Hamsten A
Atherosclerosis; 2014 Jan; 232(1):242-8. PubMed ID: 24401246
[TBL] [Abstract][Full Text] [Related]
8. Autoantibodies against oxidized low-density lipoprotein and C-reactive protein are associated with diabetes and myocardial infarction in women.
Dotevall A; Hulthe J; Rosengren A; Wiklund O; Wilhelmsen L
Clin Sci (Lond); 2001 Nov; 101(5):523-31. PubMed ID: 11672458
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies to malondialdehyde-modified low-density lipoprotein in patients with angiographically confirmed coronary artery disease.
McDowell A; Young IS; Wisdom GB
J Pharm Pharmacol; 2002 Dec; 54(12):1651-7. PubMed ID: 12542895
[TBL] [Abstract][Full Text] [Related]
10. Relationship of Autoantibodies to MDA-LDL and ApoB-Immune Complexes to Sex, Ethnicity, Subclinical Atherosclerosis, and Cardiovascular Events.
Prasad A; Clopton P; Ayers C; Khera A; de Lemos JA; Witztum JL; Tsimikas S
Arterioscler Thromb Vasc Biol; 2017 Jun; 37(6):1213-1221. PubMed ID: 28473443
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies against modified apolipoprotein B-100 in relation to low-density lipoprotein size and the metabolic syndrome in otherwise healthy men.
Sjögren P; Fredrikson GN; Rosell M; de Faire U; Hamsten A; Nilsson J; Hellenius ML; Fisher RM
Metabolism; 2008 Mar; 57(3):362-6. PubMed ID: 18249208
[TBL] [Abstract][Full Text] [Related]
12. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
[TBL] [Abstract][Full Text] [Related]
13. Decreased levels of autoantibodies against apolipoprotein B-100 antigens are associated with cardiovascular disease in systemic lupus erythematosus.
Svenungsson E; Engelbertsen D; Wigren M; Gustafsson JT; Gunnarsson I; Elvin K; Jensen-Urstad K; Fredrikson GN; Nilsson J
Clin Exp Immunol; 2015 Sep; 181(3):417-26. PubMed ID: 25959453
[TBL] [Abstract][Full Text] [Related]
14. Treatment with apo B peptide vaccines inhibits atherosclerosis in human apo B-100 transgenic mice without inducing an increase in peptide-specific antibodies.
Fredrikson GN; Björkbacka H; Söderberg I; Ljungcrantz I; Nilsson J
J Intern Med; 2008 Dec; 264(6):563-70. PubMed ID: 18783480
[TBL] [Abstract][Full Text] [Related]
15. Association between IgM against an aldehyde-modified peptide in apolipoprotein B-100 and progression of carotid disease.
Fredrikson GN; Hedblad B; Berglund G; Alm R; Nilsson JA; Schiopu A; Shah PK; Nilsson J
Stroke; 2007 May; 38(5):1495-500. PubMed ID: 17363723
[TBL] [Abstract][Full Text] [Related]
16. Low Levels of Apolipoprotein B-100 Autoantibodies Are Associated With Increased Risk of Coronary Events.
Björkbacka H; Alm R; Persson M; Hedblad B; Nilsson J; Fredrikson GN
Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):765-71. PubMed ID: 26916732
[TBL] [Abstract][Full Text] [Related]
17. High circulating autoantibodies against human oxidized low-density lipoprotein are related to stable and lower titers to unstable clinical situation.
Santos AO; Fonseca FA; Fischer SM; Monteiro CM; Brandão SA; Póvoa RM; Bombig MT; Carvalho AC; Monteiro AM; Ramos E; Gidlund M; Figueiredo Neto AM; Izar MC
Clin Chim Acta; 2009 Aug; 406(1-2):113-8. PubMed ID: 19523463
[TBL] [Abstract][Full Text] [Related]
18. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events.
Tsimikas S; Brilakis ES; Lennon RJ; Miller ER; Witztum JL; McConnell JP; Kornman KS; Berger PB
J Lipid Res; 2007 Feb; 48(2):425-33. PubMed ID: 17093289
[TBL] [Abstract][Full Text] [Related]
19. Does alpha-1-proteinase inhibitor play a protective role in coronary atherosclerosis?
Stakisaitis D; Basys V; Benetis R
Med Sci Monit; 2001; 7(4):701-11. PubMed ID: 11433198
[TBL] [Abstract][Full Text] [Related]
20. Antibodies against apoB100 peptide 210 inhibit atherosclerosis in apoE
Dunér P; Mattisson IY; Fogelstrand P; Glise L; Ruiz S; Farina C; Borén J; Nilsson J; Bengtsson E
Sci Rep; 2021 Apr; 11(1):9022. PubMed ID: 33907226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
